Tirzepatide vs Leuphasyl
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Tirzepatide
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight loss), it has shown superior weight loss results compared to semaglutide in clinical trials.
Full details →Leuphasyl
Leuphasyl (Pentapeptide-18) is a cosmetic peptide that reduces muscle tension through a mechanism similar to enkephalins. Often combined with Syn-Ake for enhanced anti-wrinkle effects.
Full details →Side-by-Side Comparison
| Aspect | Tirzepatide | Leuphasyl |
|---|---|---|
| Mechanism | Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, providing synergistic effects on insulin secretion, appetite suppression, and metabolic regulation. The dual mechanism may explain its enhanced efficacy. | Mimics enkephalin and binds to enkephalin receptors on muscle cells, reducing acetylcholine release and thereby decreasing muscle contraction intensity. |
| Typical Dosage | Start at 2.5mg weekly, titrate every 4 weeks through 5mg, 7.5mg, 10mg, 12.5mg, to maximum 15mg weekly. Full titration takes approximately 20 weeks. | Topical: 3-8% concentration in serums. Often used in combination products with other muscle-relaxing peptides. |
| Administration | Subcutaneous injection once weekly. Rotate injection sites. Slower titration may help reduce GI side effects. | Topical application to expression lines. Best results with consistent twice-daily use over 8+ weeks. |
| Side Effects | Similar to semaglutide: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite. Generally improve with continued use. | Very well-tolerated topically. No significant adverse effects reported at cosmetic concentrations. |
| Best For |